Macrophages and lymphocytes differentially modulate the ability of RANTES to inhibit HIV-1 infection.
The beta-chemokines MIP-1alpha, MIP-1beta, and RANTES inhibit HIV-1 infection of CD4+ T cells by inhibiting interactions between the virus and CCR5 receptors. However, while beta-chemokine-mediated inhibition of HIV-1 infection of primary lymphocytes is well documented, conflicting results have been obtained using primary macrophages as the virus target. Here, we show that the beta-chemokine RANTES inhibits virus entry into both cellular targets of the virus, lymphocytes and macrophages. However, while virus entry is inhibited at the moment of infection in both cell types, the amount of virus progeny is lowered only in lymphocytes. In macrophages, early-entry restriction is lost during long-term cultivation, and the amount of virus produced by RANTES-treated macrophages is similar to the untreated cultures, suggesting an enhanced virus replication. We further show that at least two distinct cellular responses to RANTES treatment in primary lymphocytes and macrophages contribute to this phenomenon. In lymphocytes, exposure to RANTES significantly increases the pool of inhibitory beta-chemokines through intracellular signals that result in increased production of MIP-1alpha and MIP-1beta, thereby amplifying the antiviral effects of RANTES. In macrophages this amplification step does not occur. In fact, RANTES added to the macrophages is efficiently cleared from the culture, without inducing synthesis of beta-chemokines. Our results demonstrate dichotomous effects of RANTES on HIV-1 entry at the moment of infection, and on production and spread of virus progeny in primary macrophages. Since macrophages serve as a reservoir of HIV-1, this may contribute to the failure of endogenous chemokines to successfully eradicate the virus.
Gross
Eleanore
E
Immunology and Inflammation Center, North Shore-LIJ Research Institute, New York, NY, USA.
Amella
Carol A
CA
Pompucci
Lorena
L
Franchin
Giovanni
G
Sherry
Barbara
B
Schmidtmayerova
Helena
H
D000163:Acquired Immunodeficiency Syndrome / Q000276:immunology / Q000517:prevention & control; D019380:Anti-HIV Agents / Q000494:pharmacology; D001692:Biological Transport; D002478:Cells, Cultured; D018946:Chemokine CCL5 / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000502:physiology*; D015658:HIV Infections / Q000276:immunology / Q000517:prevention & control*; D015497:HIV-1 / Q000187:drug effects / Q000235:genetics / Q000472:pathogenicity*; D006801:Humans; D008214:Lymphocytes / Q000187:drug effects / Q000276:immunology* / Q000821:virology*; D008264:Macrophages / Q000187:drug effects / Q000276:immunology* / Q000821:virology*; D016133:Polymerase Chain Reaction / Q000379:methods; D015728:Receptors, HIV / Q000187:drug effects / Q000502:physiology; D012016:Reference Values; D014779:Virus Replication / Q000187:drug effects; D015215:Zidovudine / Q000494:pharmacology
D019380:Anti-HIV Agents; D018946:Chemokine CCL5; D015728:Receptors, HIV; D015215:Zidovudine